Antitumor activity of irinotecan with ellagic acid in C6 glioma cells
Künye
Cetin, A., Biltekin, B., & Ozevren, H. (2022). Antitumor activity of irinotecan with ellagic acid in C6 glioma cells. Revista Da Associação Médica Brasileira, 68(7), pp. 939–944. https://doi.org/10.1590/1806-9282.20220130 Özet
OBJECTIVE: Irinotecan-based combination chemotherapies in malignant gliomas need to be examined. The aim of this study was to investigate the
synergetic effect of ellagic acid, a natural polyphenolic antioxidant compound, with irinotecan, an inhibitor of topoisomerase I enzyme, on the growth,
cadherin switch, and angiogenic processes of a glioma cell line.
METHODS: A combination of 100 μM ellagic acid and 100 μM irinotecan was applied to rat C6 glioma cells for 24th, 48th, and 72nd h. The cell
proliferation was evaluated by 5-bromo-2ʹ-deoxyuridine immunocytochemistry. The expression levels of vascular endothelial growth factor, E-cadherin,
and N-cadherin were measured using real-time polymerase chain reaction and their immunoreactivities using immunocytochemistry.
RESULTS: The treatment of irinotecan with combining ellagic acid enhanced antitumor activity and the synergistic effect of these reduced the cell
proliferation of C6 glioma by inhibiting the cadherin switch and promoting the antiangiogenic processes.
CONCLUSIONS: Further research is required to prove a negative relationship between C6 glial cell proliferation and irinotecan with ellagic acid
application. Our preliminary data suggest that even with the extremely short-term application, irinotecan with ellagic acid may affect glioma cells at
the level of gene and protein expression